6 completed. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 3 | 1 | Completed 1 |
Follow Malignant Ascites: new trials by email Literature Review of Malignant Ascites trials Research Report on Malignant Ascites
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody M701, paracentesis - Malignant Ascites | Phase 2 | Completed | Wuhan YZY Biopharma Co., Ltd. | 115 | 2021-11-24 | 2026-06-17 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, placebo, Chemotherapy - Brenner Tumor, Malignant Ascites | Phase 2 | Completed | University of Chicago | 111 | 2015-02-25 | 2026-03-27 |
| Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites Endostar, Cisplatin - Malignant Pleural Effusion, Malignant Ascites | Phase 2 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 336 | 2011-03-01 | 2014-08-01 |
| Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers Bevacizumab, Placebo - Malignant Ascites, Gastrointestinal Cancers | Phase 2 | Completed | AIO-Studien-gGmbH | 53 | 2010-02-01 | 2015-04-13 |
| Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites catumaxomab - Malignant Ascites | Phase 2 | Completed | Neovii Biotech | 32 | 2006-06-01 | 2018-10-17 |
| Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group Catumaxomab (Removab), paracentesis - EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast), Malignant Ascites | Phase 2 / Phase 3 | Completed | Neovii Biotech | 258 | 2004-09-01 | 2009-02-05 |
Carcinoma, Ovarian Epithelial (2) · Fallopian Tube Neoplasms (2) · Pleural Effusion, Malignant (2) · Ascites (1) · Brenner Tumor (1) · Carcinoma (1) · Gastrointestinal Neoplasms (1) · Neoplasms, Glandular and Epithelial (1) · Ovarian Neoplasms (1) · Peritoneal Neoplasms (1)
Neoplasms (4) · Neoplasms by Site (4) · Adnexal Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Fallopian Tube Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Neoplasms by Histologic Type (2)
Paracentesis (2) · catumaxomab (2) · Bevacizumab (1) · Cisplatin (1) · Drug Therapy (1) · Metformin (1) · endostar protein (1)
Neovii Biotech (2) · AIO-Studien-gGmbH (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · University of Chicago (1) · Wuhan YZY Biopharma Co., Ltd. (1)
China (2) · United States (2) · Germany (1)
Jianming Xu, MD (1) · Jonathan Berek, MD MMSc (1) · Karin Jordan, Dr. med. (1) · Seiko Yamada (1) · Shukui Qin, MD (1)